Negara: Kanada
Bahasa: Inggris
Sumber: Health Canada
DARIDOREXANT (DARIDOREXANT HYDROCHLORIDE)
IDORSIA PHARMACEUTICALS LTD
N05CJ03
DARIDOREXANT
50MG
TABLET
DARIDOREXANT (DARIDOREXANT HYDROCHLORIDE) 50MG
ORAL
15G/50G
Prescription
Active ingredient group (AIG) number: 0164601002; AHFS:
APPROVED
2023-04-28
_QUVIVIQ_ _TM_ _ (daridorexant) _ _Page 1 of 28_ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION Pr QUVIVIQ TM Daridorexant tablets Tablets, 25 mg and 50 mg tablets daridorexant (as daridorexant hydrochloride), Oral Hypnotic Idorsia Pharmaceuticals Ltd Hegenheimermattweg 91 4123 Allschwil Switzerland Imported and distributed in Canada by Innomar Strategies Inc. Oakville, ON L6L 0C4 Canada Date of Initial Authorization: April 26, 2023 Date of Revision: January 08, 2024 Submission Control Number: 276525 _ _ _QUVIVIQ_ _TM_ _ (daridorexant) _ _Page 2 of 28_ RECENT MAJOR LABEL CHANGES Not applicable. TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED . RECENT MAJOR LABEL CHANGES ............................................................................................ 2 TABLE OF CONTENTS .............................................................................................................. 2 PART I: HEALTH PROFESSIONAL INFORMATION ...................................................................... 4 1 INDICATIONS ............................................................................................................... 4 1.1 Pediatrics ................................................................................................................4 1.2 Geriatrics ................................................................................................................4 2 CONTRAINDICATIONS ................................................................................................. 4 4 DOSAGE AND ADMINISTRATION ................................................................................. 4 4.1 Dosing Considerations ............................................................................................4 4.2 Recommended Dose and Dosage Adjustment .......................................................4 4.5 Missed Dose ...................................................................................................... Baca dokumen lengkapnya